243 related articles for article (PubMed ID: 17150306)
21. Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography.
Guilarte TR; McGlothan JL; Foss CA; Zhou J; Heston WD; Kozikowski AP; Pomper MG
Neurosci Lett; 2005 Oct; 387(3):141-4. PubMed ID: 16006038
[TBL] [Abstract][Full Text] [Related]
22. A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
Vorlová B; Sedlák F; Kašpárek P; Šrámková K; Malý M; Zámečník J; Šácha P; Konvalinka J
Prostate; 2019 Feb; 79(2):126-139. PubMed ID: 30256431
[TBL] [Abstract][Full Text] [Related]
23. Measurement of glutamate carboxypeptidase II (NAALADase) enzyme activity by the hydrolysis of [³H]-N-acetylaspartylglutamate (NAAG).
Tiffany CW; Slusher BS
Curr Protoc Pharmacol; 2002 Feb; Chapter 3():Unit3.10. PubMed ID: 21959764
[TBL] [Abstract][Full Text] [Related]
24. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
25. GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
Vorlova B; Knedlik T; Tykvart J; Konvalinka J
Front Biosci (Landmark Ed); 2019 Mar; 24(4):648-687. PubMed ID: 30844704
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
27. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Mesters JR; Barinka C; Li W; Tsukamoto T; Majer P; Slusher BS; Konvalinka J; Hilgenfeld R
EMBO J; 2006 Mar; 25(6):1375-84. PubMed ID: 16467855
[TBL] [Abstract][Full Text] [Related]
28. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors.
Rong SB; Zhang J; Neale JH; Wroblewski JT; Wang S; Kozikowski AP
J Med Chem; 2002 Sep; 45(19):4140-52. PubMed ID: 12213057
[TBL] [Abstract][Full Text] [Related]
29. The NAAG'ing Concerns of Modeling Human Alzheimer's Disease in Mice.
Hollinger KR; Alt J; Rais R; Kaplin AI; Slusher BS
J Alzheimers Dis; 2019; 68(3):939-945. PubMed ID: 30883361
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide.
Conway RE; Rojas C; Alt J; Nováková Z; Richardson SM; Rodrick TC; Fuentes JL; Richardson NH; Attalla J; Stewart S; Fahmy B; Barinka C; Ghosh M; Shapiro LH; Slusher BS
Angiogenesis; 2016 Oct; 19(4):487-500. PubMed ID: 27387982
[TBL] [Abstract][Full Text] [Related]
31. Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain.
Surendran S; Ezell EL; Quast MJ; Wei J; Tyring SK; Michals-Matalon K; Matalon R
Brain Res; 2004 Aug; 1016(2):268-71. PubMed ID: 15246864
[TBL] [Abstract][Full Text] [Related]
32.
Morland C; Nordengen K
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163193
[No Abstract] [Full Text] [Related]
33. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Evans JC; Malhotra M; Cryan JF; O'Driscoll CM
Br J Pharmacol; 2016 Nov; 173(21):3041-3079. PubMed ID: 27526115
[TBL] [Abstract][Full Text] [Related]
35. S1 pocket of glutamate carboxypeptidase II: a new binding site for amyloid-β degradation.
Lee SK; Kim H; Cheong YH; Kim MJ; Jo SA; Youn HS; Park SI
Biochem Biophys Res Commun; 2013 Sep; 438(4):765-71. PubMed ID: 23891752
[TBL] [Abstract][Full Text] [Related]
36. MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.
Airan RD; Foss CA; Ellens NP; Wang Y; Mease RC; Farahani K; Pomper MG
Mol Imaging Biol; 2017 Feb; 19(1):24-30. PubMed ID: 27481359
[TBL] [Abstract][Full Text] [Related]
37. Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.
Knedlík T; Vorlová B; Navrátil V; Tykvart J; Sedlák F; Vaculín Š; Franěk M; Šácha P; Konvalinka J
FEBS Open Bio; 2017 Sep; 7(9):1362-1378. PubMed ID: 28904865
[TBL] [Abstract][Full Text] [Related]
38. Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Divyya S; Naushad SM; Addlagatta A; Murthy PV; Reddy ChR; Digumarti RR; Gottumukkala SR; Kumar A; Rammurti S; Kutala VK
Gene; 2012 Apr; 497(2):273-9. PubMed ID: 22310383
[TBL] [Abstract][Full Text] [Related]
39. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay.
Rojas C; Frazier ST; Flanary J; Slusher BS
Anal Biochem; 2002 Nov; 310(1):50-4. PubMed ID: 12413472
[TBL] [Abstract][Full Text] [Related]
40. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
Kim MJ; Chae SS; Koh YH; Lee SK; Jo SA
FASEB J; 2010 Nov; 24(11):4491-502. PubMed ID: 20624932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
